Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Teva to Hold Off on Generic Temodar

By Drug Discovery Trends Editor | March 18, 2010

NEW YORK (AP) – Teva Pharmaceutical Industries Ltd. agreed to hold off on launching a generic version of Merck & Co.’s cancer drug Temodar until a federal appeals court weighs in on the drug’s patent.

Instead of launching its generic version of Temodar now, Teva said it will begin selling its drug only if the court agrees that a patent on the brain cancer drug is unenforceable. In return, Merck agreed to allow Teva to start selling its generic in August 2013 if the patent is upheld. At that time, Merck will still have pediatric exclusivity on the brain cancer treatment.

Merck sued Teva for patent infringement after Teva applied for approval of its generic version of Temodar. In February, a U.S. district court said the patent supporting Temodar was unenforceable. That ruling cleared a path for Teva, the world’s largest generic drugmaker, to begin selling its version of the drug. Temodar, or temozolomide, was approved by the Food and Drug Administration in 1999.

Merck said it is defending the patent and still believes it is valid and enforceable.

Temodar was developed by Schering-Plough Corp. and the generic was developed by Barr Pharmaceuticals. Merck bought Schering-Plough in November, and Teva acquired Barr in late 2008.

In afternoon trading, shares of the Israeli company fell 39 cents to $59.95. Shares of Merck, based in Whitehouse Station, N.J., lost 19 cents to $37.75.

Date: March 17, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50